Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
Primary Objective To determine whether escalating maintenance therapy with the addition of ixazomib to lenalidomide improves overall survival among patients who are MRD positive after approximately 1 year of lenalidomide maintenance following an early stem cell transplant (≤ 12 months from diagnosis).
Secondary Clinical Objectives To establish whether progression-free survival is superior with the addition of ixazomib to lenalidomide maintenance. To evaluate best response on treatment and compare response rates between arms. To evaluate the safety profile of ixazomib added to lenalidomide and compare toxicity rates between arms.